Nanoscope presents optical gene delivery, OCT-guided electrophysiology platforms at ARVO annual meeting
Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of retinal diseases, is featuring multiple scientific presentations highlighting its groundbreaking research on optical gene delivery for vision restoration and OCT-guided electrophysiology platforms for characterization of retinal degeneration and assessment of efficacy of cell-gene therapy at the 2021 ARVO annual (virtual) meeting, May 1-7.
ARVO, the Association for Research in Vision and Ophthalmology, is the largest eye and vision research organization in the world with nearly 11,000 members in more than 75 countries.
Related Stories
Nanoscope s lead product is an optogenetic gene therapy, vMCO-010, that delivers light- sensitive Multi-Characteristics Opsin (MCO) into retinal cells to restore vision in patients with retinal degeneration. If successful, the optogenetic therapy would b
E-Mail
IMAGE: Left: OCT-guided Laser microirradiation platform for generation of retinal degeneration, gene delivery and physiological evaluation of retina function. Right: Expression of therapeutic MCO gene in specific retinal cells in laser-targeted. view more
Credit: Nanoscope Technologies LLC
ARLINGTON, TX (May 5, 2021) Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of retinal diseases, is featuring multiple scientific presentations highlighting its groundbreaking research on optical gene delivery for vision restoration and OCT-guided electrophysiology platforms for characterization of retinal degeneration and assessment of efficacy of cell-gene therapy at the 2021 ARVO annual (virtual) meeting, May 1-7.
ARVO, the Association for Research in Vision and Ophthalmology, is the largest eye and vision research organization in the world with nearly 11,000 members in more than 75 countries.
Nanoscope s Optical Gene Therapies to be Featured at Optogenetics and Optical Manipulation 2021 Conference
Company s President Samarendra Mohanty will co-chair the conference, which is part of the SPIE Photonics West Digital Forum
News provided by
Share this article
Share this article
BEDFORD, Texas, March 5, 2021 /PRNewswire/ Researchers of Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal diseases, will make multiple scientific presentations featuring its groundbreaking research on optical gene delivery and opsin based neuromodulation therapy at the Optogenetics and Optical Manipulation 2021 virtual conference, March 6 – 11, 20201.
Nanoscope President Samarendra Mohanty, Ph.D., is serving as a co-chair of the event, which is part of SPIE Photonics West s week long series of online conferences and industry programs. SPIE is an international society for optics and photonics dedicated to advancing light-bas
The first part of the pioneering test, developed by researchers at University College London, is called DARC.
DARC involves injecting dye into a person s bloodstream to illuminate stressed endothelial cells in the retina, so they appear bright white under a fluorescent camera.
These stressed retinal cells could lead to abnormalities and later leaking blood vessels – causing AMD, which can severely compromise the central field of vision.
The second part of the test uses an AI algorithm, trained to detect whether the highlighted white spots are around the macula – which indicates high AMD risk.
The AI is more objective and consistent than the judgements of human clinicians, and it can also analyse thousands of images of the retina.